Pidgeon Graham P, Lysaght Joanne, Krishnamoorthy Sriram, Reynolds John V, O'Byrne Ken, Nie Daotai, Honn Kenneth V
Department of Clinical Surgery, Trinity College Dublin, St. James Hospital, Dublin 8, Ireland.
Cancer Metastasis Rev. 2007 Dec;26(3-4):503-24. doi: 10.1007/s10555-007-9098-3.
The metabolism of arachidonic acid through lipoxygenase pathways leads to the generation of various biologically active eicosanoids. The expression of these enzymes vary throughout the progression of various cancers, and thereby they have been shown to regulate aspects of tumor development. Substantial evidence supports a functional role for lipoxygenase-catalyzed arachidonic and linoleic acid metabolism in cancer development. Pharmacologic and natural inhibitors of lipoxygenases have been shown to suppress carcinogenesis and tumor growth in a number of experimental models. Signaling of hydro[peroxy]fatty acids following arachidonic or linoleic acid metabolism potentially effect diverse biological phenomenon regulating processes such as cell growth, cell survival, angiogenesis, cell invasion, metastatic potential and immunomodulation. However, the effects of distinct LOX isoforms differ considerably with respect to their effects on both the individual mechanisms described and the tumor being examined. 5-LOX and platelet type 12-LOX are generally considered pro-carcinogenic, with the role of 15-LOX-1 remaining controversial, while 15-LOX-2 suppresses carcinogenesis. In this review, we focus on the molecular mechanisms regulated by LOX metabolism in some of the major cancers. We discuss the effects of LOXs on tumor cell proliferation, their roles in cell cycle control and cell death induction, effects on angiogenesis, migration and the immune response, as well as the signal transduction pathways involved in these processes. Understanding the molecular mechanisms underlying the anti-tumor effect of specific, or general, LOX inhibitors may lead to the design of biologically and pharmacologically targeted therapeutic strategies inhibiting LOX isoforms and/or their biologically active metabolites, that may ultimately prove useful in the treatment of cancer, either alone or in combination with conventional therapies.
花生四烯酸通过脂氧合酶途径进行的代谢会导致多种生物活性类二十烷酸的生成。这些酶的表达在各种癌症的进展过程中有所不同,因此已显示它们可调节肿瘤发展的各个方面。大量证据支持脂氧合酶催化的花生四烯酸和亚油酸代谢在癌症发展中具有功能性作用。在许多实验模型中,脂氧合酶的药理抑制剂和天然抑制剂已显示出可抑制致癌作用和肿瘤生长。花生四烯酸或亚油酸代谢后氢[过氧]脂肪酸的信号传导可能会影响多种生物现象调节过程,如细胞生长、细胞存活、血管生成、细胞侵袭、转移潜能和免疫调节。然而,不同的脂氧合酶同工型对所描述的个体机制以及所研究肿瘤的影响差异很大。5-脂氧合酶和血小板型12-脂氧合酶通常被认为具有促癌作用,15-脂氧合酶-1的作用仍存在争议,而15-脂氧合酶-2则抑制致癌作用。在本综述中,我们重点关注一些主要癌症中脂氧合酶代谢调节的分子机制。我们讨论了脂氧合酶对肿瘤细胞增殖的影响、它们在细胞周期控制和细胞死亡诱导中的作用、对血管生成、迁移和免疫反应的影响,以及这些过程中涉及的信号转导途径。了解特异性或一般性脂氧合酶抑制剂抗肿瘤作用的分子机制可能会导致设计出抑制脂氧合酶同工型和/或其生物活性代谢物的生物学和药理学靶向治疗策略,这些策略最终可能被证明单独或与传统疗法联合用于癌症治疗是有用的。